Condition

Cognition Disorders

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 29 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials29

Recruiting1

Common interventions25

Lead sponsors shown15

Clinical trials

29 shown

Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digital Testing Platform Across the LifespanNCT07763392 · 2026-03-23

Supplementation of Inulin + L. Acidophilus in Elders with T2DMNCT06830824 · 2025-03-01

NOT_YET_RECRUITING

Dual-Task Improvement in Parkinson's Via rTMSNCT07310238 · 2022-11-15

Validation of a Novel Self-Administered Cognitive Assessment Tool (CogCheck) in Patients With Mild and Major Neurocognitive Disorder Predominantly Due to Alzheimer's DiseaseNCT03672279 · 2021-07-27

Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)NCT03723356 · 2018-07-01

Freezing of Gait and CognitionNCT03477578 · 2017-12-01

Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)NCT03246269 · 2016-12-01

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research TrialsNCT02918539 · 2016-10-01

Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast CancerNCT02753036 · 2016-01-01

Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN StudyNCT02488720 · 2015-09-08

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory LossNCT02008357 · 2014-02-28

Schizophrenia Cognition Scale DevelopmentNCT02118571 · 2013-11-01

Study of Donepezil in Female Breast Cancer Survivors With Cognitive DysfunctionNCT01466270 · 2012-07-01

Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's DiseaseNCT01481961 · 2010-11-01

The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic PatientsNCT01186471 · 2010-05-01

The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.NCT01181934 · 2010-05-01

Cognitive Problems in Veterans With Heart FailureNCT01049308 · 2010-02-01

The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic PatientsNCT01137799 · 2009-08-01

Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)NCT00788918 · 2008-11-01

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) GenotypeNCT00548327 · 2007-10-01

A Study of C105 on Cognitive Dysfunction in Persons With Multiple SclerosisNCT00529581 · 2006-11-01

Trial of Memantine for Cognitive Impairment in Multiple SclerosisNCT00300716 · 2004-04-01

Treatment for Early Memory LossNCT00042172 · 2002-06-01

Brain Imaging and Mental Disorders of Aging InterventionNCT00267163 · 2000-09-01

Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.NCT00000392 · 1990-01-01

A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).NCT00000393 · 1988-01-01

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV PatientsNCT00013585

Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)NCT00000174

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's DiseaseNCT03564964

NO_LONGER_AVAILABLE

Common interventions

Leading sponsors

Janssen Pharmaceutica N.V., Belgium 3 National Institute of Mental Health (NIMH) 3 Aarhus University Hospital 1 Anahuac University 1 Andreas Monsch 1 Avid Radiopharmaceuticals 1 Carelon Research 1 Charite University, Berlin, Germany 1 Cognition Pharmaceuticals, LLC 1 Eli Lilly and Company 1 National Institute of Allergy and Infectious Diseases (NIAID) 1 National Institute on Aging (NIA) 1 Novartis 1 NYU Langone Health 1 Oregon Health and Science University 1

Trial status mix

COMPLETED21

TERMINATED3

UNKNOWN2

NO_LONGER_AVAILABLE1

NOT_YET_RECRUITING1

RECRUITING1

Phase mix

PHASE26

NA4

PHASE33

EARLY_PHASE12

PHASE12

PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.